亚太电子临床结果评估 (eCOA) 市场 – 行业趋势和 2030 年预测

亚太电子临床结果评估 (eCOA) 市场分析和规模

临床试验数量的增加对于提高合规性、有效获取和管理临床信息至关重要。降低成本的需求和研发活动的增加预计将推动市场增长。Kayentis 是一家研究电子临床结果评估 (eCOA) 解决方案的法国公司，该公司于 2020 年 12 月为该项目获得了 830 万美元的资金。这有助于其实现区域扩张和产品开发的目标。

Data Bridge Market Research 分析称，电子临床结果评估 (eCOA) 市场在 2022 年的规模为 1940 亿美元，预计到 2030 年将达到 6765.8 亿美元，在 2023 年至 2030 年的预测期内，复合年增长率为 16.90%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

亚太电子临床结果评估 (eCOA) 市场范围和细分

Market Definition

Electronic Clinical Outcome Assessment (eCOA) is a method of electronically collecting outcomes data in clinical trials. eCOA uses technologies such as handheld devices, tablets, and the internet to enable trial participants, physicians, and carers to directly report information about healthcare outcomes.

Asia-Pacific Electronic Clinical Outcome Assessment (eCOA) Market Dynamics

Drivers

• Rising burden on pharmaceutical manufacturers

To reduce overall costs, new medication development techniques are gradually relying on electronic data capture rather than paper-based procedures. Data collection via electronic clinical outcome assessment platforms provides improved data quality, harmonises data collection practises, and delivers significant value to its users, in the form of data analysis. Electronic data collection and analysis services eliminate all of the drawbacks of paper-based records while growing patient compliance. They also lower the cost of site monitoring and eliminate the risk of data fluctuation. The above mentioned advantages of using electronic clinical outcome assessments are expected to drive product demand in the coming years.

• Rise in clinical outcome assessments

Clinical outcome assessments (COAs) are thus being used more frequently to evaluate the efficacy of various chronic illness therapies. These have frequently been critical in the regulatory approval of medicines. The addition of numerous services will also aid in its growth. For instance, in June 2021, Signant Health has launched a novel acceleration programme that cuts study setup timelines by 50% or more while maintaining clinical data quality. As a result, the increasing launch of novel programmes that assist companies in evaluating clinical trial studies is likely to boost demand for electronic clinical outcome assessment solutions, thereby boosting market growth.

Opportunities

• Rising demand for electronic clinical outcome assessment solutions

In a study that was published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential therapeutics for COVID-19 were discovered using a combined virtual and experimental screening strategy and selected from a library of nearly 4,000 approved medications with hydroxychloroquine (HCQ) as a reference medication. As prospective clinical trial candidates against the early phases of SARS-CoV-2 infection, zuclopenthixol, nebivolol, and amodiaquine were suggested. Remdesivir and favipiravir treatments were also suggested as potential adjuvants in COVID-19 treatment. As more clinical trials are being conducted as a result of the repurposing of various medications, there is a greater demand for electronic clinical outcome assessment systems. There will likely be an increase in demand for electronic clinical outcome evaluation solutions.

Restraints/Challenges

• High implementation costs

Data privacy concerns and high implementation costs limit the market's growth. Moreover, over the projection period of 2023–2030, it is anticipated that the market will face challenges from a lack of favourable reimbursement scenarios in developing economies, high custom duty levied on medical equipment, and a lack of adequate infrastructure in low- and middle-income countries.

This electronic clinical outcome assessment (eCOA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the electronic clinical outcome assessment (eCOA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Electronic Clinical Outcome Assessment (eCOA) Market

COVID-19 pandemic hampered the Clinical study management. Market participants adopted numerous initiatives, including the use of eClinical technology, to address these problems and guarantee the continuance of clinical research operations. Clinical trials were digitised as a result of the epidemic. In order to gather, organise, and extract valuable insights from data in a remote, cost-effective manner, a growing number of sponsors, biopharma firms, medical device companies, and contract research organisations (CROs) have started to employ eClinical systems. Patient data can be remotely obtained with the aid of electronic clinical outcome evaluation (eCOA).

Recent Development

• 2020 年，澳大利亚墨尔本、沙特阿拉伯吉达、日本大阪、加拿大蒙特利尔和荷兰是 Oracle 扩展其云系统的五个新地区之一（阿姆斯特丹）。预计市场扩张将受益于消费者对其基于云的应用程序的认识度的提高。

• 2020 年，通过将 LifeSphere Medical Information 和 LifeSphere MultiVigilance 集成到其面向服务的技术堆栈中，Aris 与 Soterius, Inc. 合作扩大了其产品供应。

亚太地区电子临床结果评估 (eCOA) 市场范围

电子临床结果评估 (eCOA) 市场根据产品、交付模式、方法、平台和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

产品

• 本地解决方案
• 基于云的解决方案
• 基于 Web 的解决方案

交付方式

• 网站托管
• 基于云

方法

• 患者报告结果 (PRO)
• 临床医生报告结果 (ClinRO)
• 观察者报告结果 (ObsRO)
• 绩效结果 (PerfO)

平台

• 合同研究组织
• 制药和生物制药公司
• 医疗器械制造商
• 医院和临床实验室
• 咨询服务公司
• 研究与学术
• 其他的

终端用户

• 商业服务提供商
• 医院和移植中心
• 研究实验室和学术机构

电子临床结果评估 (eCOA) 市场区域分析/见解

对电子临床结果评估 (eCOA) 市场进行了分析，并按国家、产品、交付模式、方法、平台和最终用户提供了市场规模洞察和趋势。

电子临床结果评估 (eCOA) 市场报告涵盖的国家包括亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾和亚太地区 (APAC) 其他地区。

由于全国各地正在进行大量临床试验，中国电子临床结果评估 (eCOA) 市场占据主导地位。此外，该国已启动更新的新药临床试验 (IND) 审查程序，以加快新药的获取、鼓励创新并满足现有患者的需求。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

电子临床结果评估 (eCOA) 市场还为您提供每个国家/地区资本设备医疗保健支出增长、电子临床结果评估 (eCOA) 市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对电子临床结果评估 (eCOA) 市场的影响的详细市场分析。数据适用于 2011-2021 年的历史时期。

竞争格局和电子临床结果评估 (eCOA) 市场份额分析

电子临床结果评估 (eCOA) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对电子临床结果评估 (eCOA) 市场的关注有关。

电子临床结果评估 (eCOA) 市场的一些主要参与者包括：

• IBM 公司（美国）
• IQVIA（美国）​​​​​​​
• Medidata Solutions, Inc.（美国）
• Clario (美国)
• Signant Health（美国）
• TransPerfect（美国）
• Cloudbyz（美国）
• Climedo Health GmbH（德国）
• ClinCapture（美国）
• 甲骨文公司（美国）
• Paraxel International Corporation（美国）
• eClinical Solutions LLC（美国）
• OmniComm Systems, Inc.（美国）
• CRF Health（美国）

SKU-52427